 |
Changing the Treatment of Rheumatic Diseases: Optimal Use of Biologic Therapy CME Arthur Kavanaugh, MD; Paul Emery, MA, MD, FRCP; Edward C. Keystone, MD, FRCP(C); Muhammad Asim Khan, MD, MACP, FRCP; Christopher T. Ritchlin, MD DisclosuresRelease Date: January 11, 2007; Valid for credit through January 11, 2008 | Physicians - maximum of 2.0 AMA PRA Category 1 Credit(s)™ for physicians | | This CME activity is based on transcripts and slides of presentations as delivered by the faculty at the "Changing the Treatment of Rheumatic Diseases: Optimal Use of Biologic Therapy" symposium held at the Renaissance Washington Hotel Grand Ballroom in Washington, DC, on November 12, 2006. |
| Contents of This CME Activity | |
| This activity is offered in two formats. Please choose one of the versions:
Slides and Audio Version
Requires Flash 7
Download Latest Flash Player
--OR--
Slides with transcript:
- State of the Art Address: Have We Optimally Utilized Biologic Therapy in Rheumatic Diseases?
by Arthur Kavanaugh, MD
Overview of Rheumatic Diseases
TNF Inhibitors
TNF Inhibitors: Clinical Response
TNF Inhibitors: Safety and Tolerability
TNF Inhibitors: Cost-Effectiveness
Summary
- Halting Joint Destruction: Radiographic Evidence in Early RA Supports Early and Aggressive Therapy
by Paul Emery, MA, MD, FRCP
Overview of RA
Importance of Imaging in RA
Bone Loss in RA: Synovitis and Osteoclast Activation -- Pivotal Role of TNF
Impact of the Biologics on Radiographic Progression of Disease
Other Benefits of TNF Blockade: Clinical Studies
Summary
- Optimal Use of Biologic Agents in Rheumatoid Arthritis: A Case Management Approach
by Edward C. Keystone, MD, FRCP(C)
Case Presentation
Early Use of a TNF Inhibitor
Treating Moderate Disease Is Better
Case Follow-Up
Early Use of Combination Therapy
Optimizing Conventional DMARDs
Switching to Another TNF Inhibitor
Switching TNF Inhibitors to New Biologics
Conclusion
- Expanding the Spectrum for TNF Antagonists: Safety & Efficacy in the Spondyloarthropathies: Ankylosing Spondylitis
by Muhammad Asim Khan, MD
Diagnosis of Ankylosing Spondylitis
Management of Ankylosing Spondylitis
Clinical Response to TNF Antagonists
Summary
- Expanding the Spectrum for TNF Antagonists: Safety & Efficacy in the Spondyloarthropathies: Psoriatic Arthritis
by Christopher T. Ritchlin, MD
Overview
Case Presentation
Diagnosis and Management
Disease Mechanisms
Management Challenges in Psoriatic Arthritis
Summary and Conclusions
- Questions & Answers
by Arthur Kavanaugh, MD, Paul Emery, MA, MD, FRCP, Edward C. Keystone, MD, FRCP(C), Muhammad Asim Khan, MD, and Christopher T. Ritchlin, MD
Panel Discussion
- Go to Test Questions
Take this program with you! Download this Web Conference as an MP3 and load it onto your iPod or other portable audio player for audio CME on-the-go. (Right-click and select "Save Target As…" to download) These educational activities, certified by accredited providers, were not prepared by Medscape's editors, but are made available on our site as a service to our audience. Authors are routinely instructed by the provider to disclose significant financial relationships and mention of investigational drugs and unapproved indications. Medscape has received a fee for posting these activities. Direct questions or comments to: CME@webmd.net. |
| Legal Disclaimer | |
| The material presented here does not necessarily reflect the views of Medscape or companies that support educational programming on www.medscape.com. These materials may discuss therapeutic products that have not been approved by the US Food and Drug Administration and off-label uses of approved products. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or employing any therapies described in this educational activity. |
Copyright © 2006 Scientific Frontiers, Inc.All rights reserved.
|
|
 |
This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of Rosalind Franklin University of Medicine & Science and Scientific Frontiers, Inc. Rosalind Franklin University of Medicine & Science is accredited by the ACCME to provide continuing medical education for physicians.
Rosalind Franklin University of Medicine & Science designates this educational activity for a maximum of 2 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
Contact This Provider
|
|
